Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
EPZM.US

Epizyme Takeover by Ipsen Case

On June 27, 2022, Ipsen (Euronext: IPN; ADR: IPSEY) and Epizyme (Nasdaq: EPZM) announced that they have entered into a definitive merger agreement under which Ipsen will acquire Epizyme. The transaction was unanimously approved by both Ipsen and Epizyme Boards of Directors.

On August 12, 2022, Ipsen announced that acquired all outstanding shares of EPZM for $1.45 per share plus a contingent value right (CVR) of $1.00 per share.

The EPZM's average stock price in the preceding 52 weeks was around $4.5 and had been reaching $10 per share just 1 year ago which makes the deal price unreasonably low.

Taking the preceding price range and analyst valuations into account, Shareholders have grounds to believe that the Board of Directors breached its fiduciary duties by unanimously approving the deal with understated commercial terms.
Alleged Offence
Mismanagement
Misleading Statements
Financial Misrepresentation
Failure to Disclose
Malpractice
Negligence
Breach of Fiduciary duty
Omissions
Suspected Party
Directors
Management
Shareholder
Investment Bank
Service Provider
Security Type
Stocks
Trade Direction
Long
Shock Event Date
27 June 2022
Collecting participants…
Created by Stan Vick, Scout

Epizyme Inc

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The...

    Ticker
    EPZM.US
    ISIN
    US29428V1044
    CIK
    1571498
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    400 Technology Square, Cambridge, MA, United States, 02139